Compare BioNano Genomics Inc (BNGO) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Veritone Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Veritone Inc trades at $1.54 (market cap $138.04M). The key difference: Veritone Inc is far larger — about 10.1× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | VERI | |
|---|---|---|
Market Cap | $13.66M | $138.04M |
Sector | Health | Technology |
52-Week High | $4.92 | $8.39 |
52-Week Low | $1.06 | $1.00 |
Enterprise Value | $16.26M | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Veritone (VERI) trades at $1.52, up 5.56% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, though revenue remains around $90-92 million. Recent news highlights partnerships in AI and public safety, but the stock faces headwinds from a securities class action lawsuit with a July 20, 2026 deadline.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold ratings, but persistent losses and legal risks overshadow growth initiatives. Investment opportunity hinges on Veritone's ability to monetize its AI solutions and achieve profitability, while key risks include ongoing litigation and competitive pressures in the enterprise AI space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
